X
BMRN icon

Xponance’s BioMarin Pharmaceuticals BMRN Stock Holding History

Xponance’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33M Buy
23,233
+205
+0.9% +$11.2K 0.01% 694
2026
Q1 		$1.3M Buy
23,028
+5,098
+28% +$297K 0.01% 662
2025
Q4 		$1.07M Sell
17,930
-14,400
-45% -$784K 0.01% 675
2025
Q3 		$1.75M Sell
32,330
-12
-0% -$686 0.01% 576
2025
Q2 		$1.78M Buy
32,342
+465
+1% +$27.4K 0.01% 563
2025
Q1 		$2.25M Buy
31,877
+202
+0.6% +$13.6K 0.02% 495
2024
Q4 		$2.08M Buy
31,675
+2,247
+8% +$151K 0.02% 512
2024
Q3 		$2.07M Buy
29,428
+121
+0.4% +$10.1K 0.02% 508
2024
Q2 		$2.41M Buy
29,307
+11,709
+67% +$975K 0.02% 456
2024
Q1 		$1.54M Buy
17,598
+8,632
+96% +$773K 0.02% 596
2023
Q4 		$865K Sell
8,966
-203
-2% -$18K 0.01% 721
2023
Q3 		$811K Buy
9,169
+226
+3% +$20.1K 0.01% 711
2023
Q2 		$775K Buy
8,943
+2,422
+37% +$228K 0.01% 743
2023
Q1 		$634K Buy
6,521
+18
+0.3% +$1.87K 0.01% 833
2022
Q4 		$673K Buy
6,503
+2,919
+81% +$274K 0.01% 786
2022
Q3 		$304K Buy
3,584
+112
+3% +$9.97K 0.01% 993
2022
Q2 		$288K Buy
+3,472
New +$276K 0.01% 1022
2021
Q3 		– Sell
-2,746
Closed -$229K – 1187
2021
Q2 		$229K Sell
2,746
-14,189
-84% -$1.12M ﹤0.01% 1138
2021
Q1 		$1.28M Sell
16,935
-146
-0.9% -$11.9K 0.03% 406
2020
Q4 		$1.5M Buy
17,081
+71
+0.4% +$5.63K 0.03% 371
2020
Q3 		$1.29M Sell
17,010
-21
-0.1% -$2.13K 0.03% 362
2020
Q2 		$2.1M Buy
+17,031
New +$1.69M 0.05% 260

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Xponance's BMRN Position: Q2 2026 in Review

Xponance increased its BioMarin Pharmaceuticals (BMRN) stake by 0.89% in Q2 2026, buying an estimated $11.2K and bringing the position to 23,233 shares worth $1.33M. The position accounts for 0.01% of the portfolio, ranked #694.

Xponance first reported a position in BMRN in Q2 2020 and has held it in 22 quarters since. The position peaked at $2.41M in Q2 2024. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Xponance held 23,233 shares of BioMarin Pharmaceuticals worth $1.33M as of Q2 2026.
  • Xponance bought 205 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $11.2K.
  • BioMarin Pharmaceuticals made up 0.01% of Xponance's portfolio in Q2 2026, its #694 holding.
  • Xponance first reported a position in BioMarin Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • Xponance's BioMarin Pharmaceuticals position peaked at $2.41M in Q2 2024.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.